Northwestern Medicine Selects Tempus to Expand Genomic Testing

Why It Matters

By integrating Tempus’s comprehensive genomic platform, Northwestern can offer more precise, data‑driven cancer care, potentially improving outcomes and accelerating trial enrollment, while Tempus expands its market foothold in a leading academic health system.

Key Takeaways

• Northwestern partners with Tempus for broad genomic testing
• Includes DNA, RNA, liquid biopsy, MRD analyses
• Targets early-stage and all cancer types
• Aims to accelerate personalized therapy adoption
• Supports design of innovative clinical trials

Pulse Analysis

The alliance between Northwestern Medicine and Tempus reflects a growing industry shift toward integrating large‑scale genomic profiling into routine oncology practice. As hospitals seek to move beyond traditional histology, partnerships with data‑rich companies enable rapid deployment of next‑generation sequencing across diverse patient cohorts. Northwestern’s status as an NCI‑designated Comprehensive Cancer Center adds credibility, while Tempus brings a scalable infrastructure that can handle high‑volume testing without compromising turnaround times.

Tempus’s testing portfolio—solid‑tissue DNA and RNA sequencing, liquid biopsy, and minimal residual disease (MRD) monitoring—offers clinicians a multidimensional view of tumor biology. For early‑stage patients, these insights can identify actionable mutations before metastasis, guiding targeted therapies and sparing unnecessary treatments. The generated molecular data also feed into real‑world evidence studies, helping physicians match patients with emerging drugs and clinical trials more efficiently than ever before.

From a market perspective, the deal positions Tempus to deepen its penetration in academic health systems, a segment traditionally dominated by legacy labs. Northwestern gains a competitive edge by expanding its precision‑oncology repertoire, potentially attracting more referrals and research funding. As reimbursement models evolve to reward value‑based care, the ability to demonstrate improved outcomes through genomics will become a key differentiator, driving further collaborations across the healthcare ecosystem.